287
Participants
Start Date
October 31, 2014
Primary Completion Date
May 31, 2015
Study Completion Date
May 31, 2015
Adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29)
A 0.25 mL (for children 6 to \<36 months old) and 0.5 mL (for children ≥36 months to \< 72 months old) dose of aTIV, a trivalent (surface antigen, formaldehyde-inactivated) influenza virus vaccine, adjuvanted with MF59C.1, administered at day 1 (for all subjects) and day 29 (for naïve subjects).
Non-adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29).
A 0.25 mL (for children 6 to \<36 months old) and 0.5 mL (for children ≥36 months to \< 72 months old) dose of TIV , an egg-derived trivalent split influenza vaccine licensed in Mexico, administered at day 1 (for all subjects) and day 29 (for naïve subjects)
03, Centro Médico Universitario, Colonia Chamilpa, Cuernavaca
02, Unidad de Atencion Medica E Investigacion En Salud S.C (Unamis), Mérida
04, Medical Care and Research S.A. de C.V., Mérida
Lead Sponsor
Novartis Vaccines
INDUSTRY